KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Inventory (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Inventory for 16 consecutive years, with $5.4 billion as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Inventory changed 0.48% year-over-year to $5.4 billion, compared with a TTM value of $5.4 billion through Sep 2024, changed 0.48%, and an annual FY2023 reading of $5.1 billion, down 9.69% over the prior year.
  • Inventory was $5.4 billion for Q3 2024 at Thermo Fisher Scientific, up from $5.2 billion in the prior quarter.
  • Across five years, Inventory topped out at $5.7 billion in Q4 2022 and bottomed at $13.0 million in Q4 2021.
  • Average Inventory over 5 years is $4.7 billion, with a median of $5.1 billion recorded in 2024.
  • The sharpest move saw Inventory plummeted 99.66% in 2021, then soared 43915.38% in 2022.
  • Year by year, Inventory stood at $4.0 billion in 2020, then increased by 25.37% to $5.1 billion in 2021, then rose by 11.54% to $5.6 billion in 2022, then fell by 9.69% to $5.1 billion in 2023, then rose by 6.72% to $5.4 billion in 2024.
  • Business Quant data shows Inventory for TMO at $5.4 billion in Q3 2024, $5.2 billion in Q2 2024, and $5.1 billion in Q1 2024.